


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended): A compound represented by formula (I)



wherein is a single bond or a double bond,

is  $\alpha$ -configuration,  $\beta$ -configuration or a voluntary mixture of  $\alpha$ -configuration


and  $\beta$ -configuration,

D is  $-\text{COOR}^1$  or tetrazolyl,

$\text{R}^1$  is hydrogen or C1-4 alkyl,

G is ringA or C1-4 alkylene,

ringA is



$\text{R}^2$  is a halogen atom, C1-4 alkyl or C1-4 alkoxy,

p is 0 or an integer of 1-4,


when p is 2 or more, plural  $R^3$ 's are the same or different,

Y is a single bond or -S-,

T is oxygen or sulfur,

X is -CH<sub>2</sub>-, -O- or -S-,

ringB is C3-7 cycloalkyl optionally substituted,



wherein  $R^3$  is (1) a halogen atom, (2) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (3) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (4) C1-4 alkyl substituted with C1-4 alkoxy, (5) phenyl or (6) 3- to 15- membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (5) phenyl or (6) heterocyclic aryl in  $R^3$  is optionally substituted with 1-3 of (a) halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

q is 0 or an integer of 1-5,


when q is 2 or more, plural  $R^3$ 's are the same or different, and

n is an integer of 1-4,

a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof.


2. (canceled).

3. (currently amended): The compound according to claim 1, which is represented by formula (I-1):




wherein  $G^1$  is ring  $A^1$  or C1-4 alkylene,

ring  $A^1$  is



wherein left-pointing arrow represents binding to S, and right-pointing arrow represents binding to  $COOR^1$ ,

ring  $B^1$  is C3-7 cycloalkyl,



ring  $B^1$  may be substituted with a halogen atom, C1-4 alkyl, phenyl, methoxymethyl, trifluoromethyl and/or trifluoromethoxy,

other symbols have the same meanings as described in claim 1, and

wherein when T is oxygen, X is  $-CH_2-$ , and

when n is an integer of 2-4,  $G^1$  is ring  $A^1$ .

4. (currently amended): The compound according to claim 3, which is selected from the group consisting of:

- (1) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (2) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-ethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (3) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (4) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(naphthalene-2-yl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (5) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (6) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (7) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(4-fluoro-3-methylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (8) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3,5-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (9) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;

- (10) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(4-fluoro-3-trifluoromethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (11) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-trifluoromethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (12) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3,4-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (13) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-phenyl-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (14) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-propylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (15) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (16) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-ethyl-4-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-aza-10-oxaprost-13-enoic acid;
- (17) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-phenyl-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene;
- (18) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-methylphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene;
- (19) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene;

~~(20) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene;~~

~~(21) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-aza-10-oxaprost-13-ene;~~

~~(22) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-phenylphenyl)-5-(5-carboxythiophene-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(23) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(5-carboxythiophene-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(24) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-5-(5-carboxythiophene-  
2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(25) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(5-carboxythiophene-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(26) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-methylphenyl)-5-(5-carboxythiophene-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(27) — (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-5-(5-  
carboxythiophene-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(28) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fluoro-3-phenylphenyl)-5-(4-carboxythiazol-2-  
yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

~~(29) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-ethylphenyl)-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;~~

(30) ——— (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(naphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;

(31) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(32) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

(33) ——— (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cyclopropyl-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;

(34) ——— (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cyclohexyl-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;

(35) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-5-(5-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene, and

(36) ——— (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cyclobutyl-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;


(37) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(4-chlorophenyl)-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;

(38) ——— (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-cycloheptyl-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;

(39) ——— (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(indane-2-yl)-5-(4-carboxythiazol-2-yl)-  
1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;


- (40) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(tetrahydropyran-4-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (41) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(7-methylnaphthalene-2-yl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (42) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(4-fluorophenyl)-17,18,19,20-tetranol-5,10-dithia-8-azaprost-13-enoic acid;
- (43) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(4-fluorophenyl)-17,18,19,20-tetranol-6-thia-8-azaprost-13-enoic acid;
- (44) ——— (15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-methylphenyl)-17,18,19,20-tetranol-6-thia-8-azaprost-13-enoic acid; and
- (45) ——— (15 $\alpha$ ,13E) 9-thioxo-15-hydroxy-16-(4-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid.

5. (currently amended): The compound according to claim 1, which is represented by formula (I-2):



wherein G<sup>2</sup> is





wherein left-pointing arrow represents binding to  $-(CH_2)_2-$ , and right-pointing arrow represents binding to D,

$R^4$  is (1) a halogen atom, (2) C1-4 alkyl, (3) C1-4 alkoxy, (4) C1-4 alkyl optionally substituted with 1-5 of halogen atom(s), (5) C1-4 alkoxy optionally substituted with 1-5 of halogen atom(s), (6) phenyl or (7) 3- to 15- membered mono-, bi- or tri-heterocyclic aryl containing 1 to 4 hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulfur atom(s) which may be partially or fully saturated, and (6) phenyl or (7) heterocyclic in the  $R^4$  may be substituted with 1-3 of (a) a halogen atom(s), (b) C1-4 alkyl, (c) C1-4 alkoxy and/or (d) nitro,

$r$  is an integer 1 to 5, and

other symbols have the same meanings as described in claim 1.

6. (currently amended): The compound according to claim 5, which is selected from the group consisting of:

- (1) ~~(15*α*,13E)~~ 1,6 (1,4-interphenylene) 9-oxo-15-hydroxy-16 (3,5-dimethylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (2) ~~(15*α*,13E)~~ 1,6 (1,4-interphenylene) 9-oxo-15-hydroxy-16 (3-(benzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

- (3) ——— (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(4-fluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (4) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (5) ——— (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(5-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (6) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (7) ——— (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(6-methylbenzoxazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (8) ——— (15 $\alpha$ ,13E)-1,6-(1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-(4-methylbenzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (9) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(4-methylbenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (10) ——— (15 $\alpha$ ,13E)-1,6-(2-fluoro-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (11) ——— (15 $\alpha$ ,13E)-1,6-(3-methyl-1,4-interphenylene)-9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid;
- (12) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5,7-dimethylbenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,

- (13) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (14) ——— (15 $\alpha$ ,13E) 1,6 (1,4 interphenylene) 9-oxo-15-hydroxy-16-(3-(5-chlorobenzothiazol-2-yl)phenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (15) (15 $\alpha$ )-9-oxo-15-hydroxy-16-(3-(2,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene,
- (16) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(3,4-dimethylphenyl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene, and
- (17) ——— (15 $\alpha$ ,13E) 1,6 (1,4 interphenylene) 9-oxo-15-hydroxy-16-(3,4-difluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (18) ——— (15 $\alpha$ ,13E) 1,6 (2-methyl-1,4 interphenylene) 9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (19) (15 $\alpha$ ,13E)-9-oxo-15-hydroxy-16-(3-(5-chlorobenzoxazol-2-yl)phenyl)-5-(4-carboxythiazol-2-yl)-1,2,3,4,17,18,19,20-octanol-5-thia-8-azaprost-13-ene;
- (20) ——— (15 $\alpha$ ,13E) 1,6 (1,4 interphenylene) 9-oxo-15-hydroxy-16-(3-methyl-4-fluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (21) ——— (15 $\alpha$ ,13E) 1,6 (1,4 interphenylene) 9-oxo-15-hydroxy-16-(3-chloro-4-fluorophenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,
- (22) ——— (15 $\alpha$ ,13E) 1,6 (3-methoxy-1,4 interphenylene) 9-oxo-15-hydroxy-16-(3-methylphenyl)-2,3,4,5,17,18,19,20-octanol-8-azaprost-13-enoic acid,

- (23) ——— ~~(15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-trifluoromethoxyphenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,~~
- (24) ——— ~~(15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3,5-difluorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,~~
- (25) ——— ~~(15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-(phenyl)phenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid,~~
- (26) ——— ~~(15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-(4-fluorophenyl)phenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid, and~~
- (27) ——— ~~(15 $\alpha$ ,13E) 9-oxo-15-hydroxy-16-(3-phenyl-4-fluorophenyl)-17,18,19,20-tetranol-5-thia-8-azaprost-13-enoic acid.~~

7. (previously presented): A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, a salt thereof, a solvate thereof, a cyclodextrin clathrate thereof, or a prodrug thereof, and a pharmaceutically acceptable carrier.

8-10. (canceled).

11. (previously presented): The compound according to claim 1, wherein n is 1 or 2.